Taysha regains full rights to TSHA-102 for Rett syndrome after Astellas option expires

Taysha Gene Therapies, Inc.

Regained full rights to lead TSHA-102 program after 2022 Option Agreement with Astellas expired.
TSHA-102 has FDA Breakthrough Therapy designation; Part A REVEAL data showed 100% response rate on primary endpoint.
REVEAL pivotal trial dosing of first patient scheduled this quarter; FDA alignment on protocol and SAP obtained.
Unencumbered rights enable full strategic flexibility and optionality for Taysha.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.